Posted by Michael Wonder on 13 Jun 2023
Eupraxia Pharmaceuticals receives US FDA fast track designation for EP-104IAR in treatment of osteoarthritis
13 June 2023 - Eupraxia Pharmaceuticals today announced that the US FDA has granted fast track designation for the investigation of EP-104IAR in the treatment of adults with osteoarthritis of the knee.
Eupraxia continues to advance its ongoing Phase 2 trial evaluating EP-104IAR's safety and efficacy as a treatment candidate for knee osteoarthritis and expects to report top-line data results in the second quarter of 2023.
